New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...

Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center recently opened the Roswell Park GMP Engineering & Cell Manufacturing Facility, a $98 million cell and gene therapy hub aimed at growing ...

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...

Researchers have engineered CAR-T cells armed with computationally designed protein binders that eliminated glioblastoma ...

Broad-spectrum antibiotic use before and after CAR T correlates with worse overall survival and increased neurotoxicity, although confounding exists because antibiotics cluster with cytokine release ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...

Osteosarcoma is the most common bone cancer in children and adolescents and occur in young as well as older adults. While outcomes for localized disease have improved over time, patients with ...

After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...

Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend ...